Identifying & Developing Cyclic Peptide KRAS Inhibitors Through a Novel Screening Platform

Time: 12:15 pm
day: Day Two Track A AM


  • Showcasing how Curve’s MicrocycleTM drug discovery platform utilizes a genetically-encoded intracellular library of 3.2 x 106 cyclic peptides in combination with mammalian cell-based screening for inhibitor identification
  • Examining how intracellular screening holds several advantages over traditional in vitro screening approaches to drug discovery and has led to the identification of a series of KRAS inhibitors
  • Understanding how these molecules are currently being developed towards the clinic and how the hexameric backbone of MicrocyclesTM allows rapid scaffold-hopping the pharmacophore from a peptide into a small molecule backbone